Cystic Fibrosis Research and Translation Centers
Alabama
UAB
+
-
University of Alabama at Birmingham Gregory Fleming James Cystic Fibrosis Research Center
Director: Steven M. Rowe, MD, MSPH
The UAB CF Research Center is dedicated to providing a comprehensive, multidisciplinary understanding of CF pathogenesis and advancing innovative therapies to increase life expectancy and quality of life for people with CF. To fulfill this vision, the Center strives to position its Research Base with superior resources, expertise, and a state-of-the-art framework to conduct a broad array of CF research, focusing on research initiatives with a high likelihood of stimulating or advancing therapeutic translation.
UCSF
UCSF
+
-
University of California San Francisco Novel Small-Molecule Therapies for Cystic Fibrosis
Director: Alan S. Verkman, MD, PhD
The focus of the UCSF Core Center remains the discovery and evaluation of novel small-molecule therapies for CF. The mission of the Novel Small-Molecule Therapies for Cystic Fibrosis Center is to progress the five years of work establishing a unique academic drug discovery program in the laboratories of Dr. Verkman and collaborators to identify and characterize small-molecule modulators of CFTR activity.
Iowa
Iowa
+
-
University of Iowa Center for Gene Therapy of Cystic Fibrosis
Director: John F. Engelhardt, PhD
The Center for Gene Therapy of Cystic Fibrosis (CF) seeks to improve the quality of life for CF patients by both enhancing the field's understanding of CF pathogenesis and developing molecular therapies. The Center acts as a conduit that brings new talented investigators into the field of CF research and enhances the research infrastructure needed for collaborative discoveries and the development of novel therapies.
UNC
UNC
+
-
Marsico Lung Institute / University of North Carolina Cystic Fibrosis Center
Director: Richard C. Boucher, MD
The Marsico Lung Institute / UNC Cystic Fibrosis Center has a rich tradition of collaboration. It exhibits a wide scope but “thin” coverage of the scientific areas relevant to CF. In brief, we typically have recruited only one or two experts in a given field, but have attempted to use our large numbers of investigators to cover a wide spectrum of scientific disciplines required to tackle CF research in a collaborative and efficient fashion.
Pennsylvania
UPenn
+
-
University of Pennsylvania Molecular Therapy for Cystic Fibrosis
Director: James M. Wilson, MD, PhD
The Molecular Therapy for Cystic Fibrosis at UPenn has been transformed into a consortium consisting of four renowned institutions with a long-standing history in basic and translational CF research: UPenn, University of Massachusetts Medical School, Johns Hopkins University and the United Kingdom CF Gene Therapy Consortium. Each of these centers brings with it experience in vector development, animal models, airway gene delivery, design and support of IND-enabling studies and progression into clinical trials to support the mission of our Center which is innovative translational research for CF therapies.
Pittsburgh
Pitt
+
-
University of Pittsburgh Cystic Fibrosis Research Center
Director: Raymond A. Frizzell, PhD
The central goal of the Cystic Fibrosis Research Center (CFRC) at the University of Pittsburgh is to understand the basic mechanisms of CF disease and translate that understanding to provide improved treatments that will enhance the quality of life and lifespan of CF patients. Our strategy is to implement this goal using the Center's strengths in the Molecular and Cell Biology of CFTR, CFTR mutants and other transporters, Infection and Inflammation, with the overall theme of translating our preclinical science discoveries into clinical investigations.
Washington
Washington
+
-
University of Washington Cystic Fibrosis Research Translation Center
Director: Bonnie Ramsey, MD, Co-Director: Peter Greenberg, MD
The UW CFRTC focuses its research on developing new and improved treatments for patients with Cystic Fibrosis. The Center has a long history of strong partnerships between laboratory and clinically based scientists working together to take observations from the laboratory and transforming these findings into better drugs to treat the nutritional, metabolic and lung aspects of this fatal genetic disease.